Literature DB >> 22812908

Contact allergy to local anaesthetics-value of patch testing with a caine mix in the baseline series.

Ana Brinca1, Rita Cabral, Margarida Gonçalo.   

Abstract

BACKGROUND: Contact allergy to local anaesthetics is relatively common. Patch testing with benzocaine in the European baseline series is recommended for diagnosis, even though a caine mix has been previously suggested to be superior.
OBJECTIVES: To assess the frequency and patterns of contact allergy to local anaesthetics by using a caine mix (benzocaine, tetracaine, and cinchocaine) in the baseline series, and evaluate its efficiency as compared with benzocaine alone.
METHODS: We reviewed the results of 2736 patch tests performed between 2000 and 2010, identifying patients with positive reactions to caine mix or to one of seven local anaesthetics.
RESULTS: One hundred and twelve patients (4.1%) had at least one allergic reaction to local anaesthetics; 86 were tested with all seven local anaesthetics, resulting in 71 reactions in 53 patients. Cinchocaine gave the most reactions (50.7%); these occurred as a single reaction in 83.3% of patients, mostly with current or past relevance (97%). Benzocaine represented 22.5% of reactions, many of which were non-relevant (44%) or resulting from cross-reactions with para-compounds.
CONCLUSIONS: Almost 70% of allergic reactions to local anaesthetics would have been missed if benzocaine had been used as a screening allergen. This study supports a recommendation to replace benzocaine with a caine mix containing cinchocaine in the baseline patch test series.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22812908     DOI: 10.1111/j.1600-0536.2012.02149.x

Source DB:  PubMed          Journal:  Contact Dermatitis        ISSN: 0105-1873            Impact factor:   6.600


  1 in total

1.  The Rare Case of a Probably True IgE-Mediated Allergy to Local Anaesthetics.

Authors:  Christina Fellinger; Felix Wantke; Wolfgang Hemmer; Gabriele Sesztak-Greinecker; Stefan Wöhrl
Journal:  Case Rep Med       Date:  2013-05-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.